Bank Of Montreal Crispr Therapeutics Ag Transaction History

Bank Of Montreal

$214 Billion
Q3 2024

A detailed history of Bank Of Montreal transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Bank Of Montreal holds 5,620 shares of CRSP stock, worth $224,912. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,620

Previous 7,556 25.62%

Holding current value

$224,912

Previous $408,000 35.29%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$44.62 - $62.75 $86,384 - $121,484	-1,936 Reduced 25.62%	5,620 $264,000
Q2 2024 Aug 14, 2024	BUY	$51.17 - $68.18 $80,541 - $107,315	1,574 Added 26.31%	7,556 $408,000
Q1 2024 May 13, 2024	BUY	$60.67 - $89.12 $156,649 - $230,107	2,582 Added 75.94%	5,982 $407,000
Q4 2023 Feb 08, 2024	SELL	$38.62 - $72.18 $70,944 - $132,594	-1,837 Reduced 35.08%	3,400 $212,000
Q3 2023 Nov 01, 2023	SELL	$45.39 - $59.0 $8,987 - $11,682	-198 Reduced 3.64%	5,237 $237,000
Q2 2023 Aug 02, 2023	BUY	$43.47 - $67.77 $236,259 - $368,329	5,435 New	5,435 $305,000
Q3 2022 Nov 10, 2022	SELL	$61.1 - $83.78 $18,879 - $25,888	-309 Reduced 7.33%	3,904 $265,000
Q2 2022 Aug 11, 2022	SELL	$43.23 - $73.83 $5 Million - $8.55 Million	-115,742 Reduced 96.49%	4,213 $313,000
Q1 2022 May 12, 2022	BUY	$53.19 - $79.24 $6.12 Million - $9.11 Million	115,003 Added 2322.35%	119,955 $7.75 Million
Q4 2021 Feb 11, 2022	BUY	$70.09 - $111.29 $88,033 - $139,780	1,256 Added 33.98%	4,952 $397,000
Q3 2021 Nov 12, 2021	BUY	$110.2 - $156.64 $114,828 - $163,218	1,042 Added 39.26%	3,696 $416,000
Q2 2021 Aug 12, 2021	BUY	$100.84 - $161.89 $267,629 - $429,656	2,654 New	2,654 $387,000

Others Institutions Holding CRSP

# of Institutions

490

Shares Held

58M

Call Options Held

1.1M

Put Options Held

1.9M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.12B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account